Skip to content
Open access

Remission status in persistent depressive disorder following acute treatment with psychotherapy plus medication or medication alone: A 2-year naturalistic follow-up.

Sep 2026 · Journal of Affective Disorders · Vol 415, pp. 122506 · 1 citation · 54 references
Medicine

TL;DR

Similar to the acute phase outcomes, no group differences emerged over the 2-year follow-up, suggesting no long-term benefit of a 12-week CBASP treatment with ADM over other PDD treatments.

Abstract

Objective

Long-term benefits of acute-phase treatments for persistent depressive disorder (PDD) are unclear. Treatment guidelines disagree on the efficacy of cognitive behavioral analysis system of psychotherapy (CBASP). We examined whether acute CBASP protected against recurrence in PDD patients over two years of naturalistic follow-up.

Methods

An observational study evaluated major depressive episode (MDE) recurrences in patients completing the Research Evaluating the Value of Augmenting Medication with Psychotherapy (REVAMP) trial. Enrollees 18-75 years had PDD: current chronic MDE, recurrent MDEs with incomplete recovery, or double depression. All received open-label antidepressant medication (ADM) for 12 weeks. Non-remitters, continuing on ADM, were randomized (2:2:1) to 12 weeks of 1) CBASP, 2) brief supportive therapy (BSP), or 3) ADM alone (MEDS). Patients completing this 12-week randomized phase were offered two-year follow-up. Blinded raters assessed the primary outcome, remission status, using the Longitudinal Interval Follow-up Evaluation and Hamilton Depression Rating Scale at 3-month intervals. Analyses evaluated group differences and non-specific predictors of remission status.

Results

Of 323 participants entering follow-up, 203 (62.8%) met current MDE criteria during follow-up, without between-group differences: BSP: 83 (65.3%), CBASP: 85 (60.2%), MEDS: 35 (63.6%), Chi-square = 0.75; p = 0.69. Remission after acute treatment, lack of comorbid anxiety disorder, and female gender were significantly associated with lower recurrence risk.

Conclusion

Similar to the acute phase outcomes, no group differences emerged over the 2-year follow-up, suggesting no long-term benefit of a 12-week CBASP treatment with ADM over other PDD treatments. Findings underscore the difficulty of PDD treatment and the importance of acute treatment remission. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT00057551.

Read PDF

Similar papers

Open access Sep 2026

Predictors and Moderators of Post-Treatment Depression Severity After Hypnotherapy and Cognitive Behavioral Therapy in an RCT for Mild-to-Moderate Depression

It was found that lower baseline depression severity and higher self-efficacy predicted a better overall treatment outcome for all patients, and antidepressant medication and environmental quality of life predicted treatment outcome for patients receiving hypnotherapy.

Anna-Lena Brockmann, Lucia Pfeiffer, Anil Batra et al. · 0 citations
Open access Oct 2026

Remission Trajectories During Low-Intensity Cognitive Behavioural Therapy for Obsessive–Compulsive Disorder: A 2-Year Naturalistic Follow-Up Study

Background and Objectives: Cognitive-behavioural therapy (CBT) for obsessive–compulsive disorder (OCD) has primarily been evaluated in short-term, high-intensity treatment protocols. However, remission trajectories during low-intensity CBT (LiCBT) delivered in routine clinical practice remain insufficiently characteris...

K. Mukai, Naomi Matsuura, Y. Hosoi et al. · 0 citations
Open access Sep 2026

One-Day Cognitive Behavioural Therapy for Major Depressive Disorder: A Randomised Controlled Trial in China

The translation of evidence-based psychological treatments into accessible, real-world care remains a central challenge in global mental health implementation. Although approximately 3.4% of Chinese adults meet criteria for Major Depressive Disorder (MDD), only around 12% receive any form of treatment. Developing brief...

Nai-Hong Xu, Dong-Rong Zhao, Hao-Ke Li et al. · 0 citations
Review Open access Aug 2026

Cognitive Behavioural Therapy as an Adjunct to Pharmacotherapy in Bipolar Disorder: A Systematic Review of Treatment Outcomes and Relapse Prevention

Bipolar disorder is a chronic psychiatric condition characterized by recurrent mood episodes and significant functional impairment. Although pharmacotherapy remains the primary treatment, relapse rates remain high, highlighting the need for effective adjunctive interventions. This study aimed to synthesize evidence on...

A. C. Phelps, Hendsun Hendsun, Ernawati Ernawati · 0 citations
Sep 2026

Clinical correlates of non-responders to ketamine in terms of self-assessed life engagement among treatment-resistant depression patients.

Le non-response among TRD patients was associated with depression later onset, prior ECT, absence of diabetes, and occupational inactivity, and Pharmacological treatment alone may be insufficient to improve LE, underscoring the need to integrate psychosocial and behavioral interventions.

M. Walaszek, W. Cubała, K. Pastuszak et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.